BioWorld Asia

Jan. 12, 2011

Biotie Beefs up CNS Pipe with $120M Synosia Buy

LONDON – Biotie Therapies Corp. is acquiring Synosia Therapeutics Holding AG in an all-share deal that values the private Swiss company at €93.6 million (US$120.95 million). (BioWorld International) Read More

Symphogen Financing Largest for Private European Biotech

Immutep Lands $100M License for Autoimmune Drugs with GSK

Human Protein Can Turn on Immune Response to Cancer

Neurosearch Restructures, Preps to Market Huntexil

Cell Medica to Automate Cell Therapy for Commercialization

Spirogen, Genentech Ink Antibody Drug Conjugate Deal

Santaris and Pfizer Agree to $614M RNA Collaboration

Amarin Raises $91.2M in Public Offering for AMR101 Sales Prep

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 11, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...